Company news

MiNK Therapeutics, Inc. news in 2024

MiNK Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

December 17, 2024

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

November 13, 2024

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

November 10, 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

October 30, 2024

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

October 7, 2024

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

October 3, 2024

MiNK Reports Second Quarter 2024 Results and Business Update

August 12, 2024

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

July 31, 2024

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

July 30, 2024

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 21, 2024

MiNK Reports First Quarter 2024 Results

May 13, 2024

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 12, 2024

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

April 29, 2024

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

April 7, 2024

MiNK Reports Fourth Quarter and Year-End 2023 Results

March 20, 2024

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

March 6, 2024

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

March 5, 2024

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

February 13, 2024

Calls in 2024